中新集團(601512.SH):擬參投峯瑞資本蘇州天使基金 聚焦投資醫療及科技等領域
格隆匯11月16日丨中新集團(601512.SH)公佈,公司擬作為有限合夥人以自有資金參與投資蘇州峯瑞睿佳創業投資中心(有限合夥)(簡稱“峯瑞資本蘇州天使基金”、“標的基金”),重點聚焦醫療及科技等領域的企業進行股權投資或準股權投資或從事與投資相關的活動。該基金於2021年12月完成工商註冊,已於2022年5月16日完成中基協備案(備案號:SVH887),首次關閉規模為2.45億元。標的基金本輪擬主要引進多家機構投資者,目標規模為4-5億元,最終以實際募集情況為準。公司擬認繳出資不超過6000萬元,且佔比不超過最終基金認繳總額的15%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.